Success Stories: A Postdoctoral fellow Achieves NIW and EB1A Cases Approvals with the Help of Our Assistance
Client’s Testimonial:
“Thanks a lot for your help.”
On July 19th, 2022 and February 2nd, 2023, we received another EB-2 NIW (National Interest Waiver) approval and EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: China
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: July 19th, 2022 (NIW) and February 2nd, 2023 (EB1A)
Processing Time: 5 months, 12 days (NIW) and 10 days (EB1A) (Premium Processing Requested)
Case Summary:
A Postdoctoral Fellow contacted our law firm to help her establish her significant contributions to the U.S. by filing for an EB-2 NIW (National Interest Waiver) petition. It’s a part of our job to evaluate our client’s qualifications and research background to certify the integrity of her credentials. So, after successfully checking her achievements, we submitted her NIW case to the USCIS. She even retained our services to construct another petition under the EB-1A (Alien of Extraordinary Ability) visa category. We presented her exceptional professional background and unparalleled experience important to her current and future work at the USCIS.
Upon reviewing her credentials, we found that our client is a Postdoctoral Fellow in Biomedical Science and has accomplished a great publication record in her field:
- Her research resulted in 15 peer-reviewed scientific articles and these papers have been published in some of the most discerning, high-impact journals in her field.
- She has conducted at least 55 reviews for journals to date.
- Her work has been cited by other scholars in numerous published articles as well. According to Google Scholar, her work has been cited 359 times.
- Her study has received funding from the National Natural Science Foundation of China, the Ministry of Science and Technology of China, the National Institutes of Health, the V Foundation, and the Leukemia Research Foundation.
Her case was further supported by including four recommendation letters that she obtained from her fellow experts in the field. One of the recommenders stated:
“Taking into consideration her exceptional qualifications and her history of innovation and leadership in her field, I would strongly advise that [client] is admitted as a United States resident. Her unique combination of advanced academic qualifications, high-level research pursuits, and significant findings make [client] an invaluable asset to the United States in the field of biomedical sciences.”
The above testimonial thus proves that our client’s continued participation is critical to the overall success of developing improved treatments for cancer in the field of endeavor. Therefore, her past and current achievements suggest that she will continue to provide substantial benefits to the United States.
Our team’s efforts successfully paid off in conveying to the USCIS that our client’s expansive experience in the field of biomedical science has afforded her vast knowledge and formidable skills, which are a significant asset to any research setting and thus set her apart as an essential researcher in her field of expertise today. We would like to congratulate her on securing both the I-140 approvals and thanks to the Premium Processing service upgrade for her EB1A case, which was adjudicated in only 10 days instead of 9-12 months. We wish her to receive her green card as soon as possible.